

Engineering Conferences International ECI Digital Archives

Cell Culture Engineering XV

Proceedings

Spring 5-13-2016

Retrospective implementation of quality by design for legacy commercialized enzyme replacement therapies

Anup Agarwal

Shire Pharmaceuticals, anagarwal@shire.com

Eric Hayduk

Shire Pharmaceuticals

Follow this and additional works at: http://dc.engconfintl.org/cellculture_xv

 Part of the [Biomedical Engineering and Bioengineering Commons](#)

Recommended Citation

Anup Agarwal and Eric Hayduk, "Retrospective implementation of quality by design for legacy commercialized enzyme replacement therapies" in "Cell Culture Engineering XV", Robert Kiss, Genentech Sarah Harcum, Clemson University Jeff Chalmers, Ohio State University Eds, ECI Symposium Series, (2016). http://dc.engconfintl.org/cellculture_xv/244

This Abstract is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Cell Culture Engineering XV by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.

RETROSPECTIVE IMPLEMENTATION OF QUALITY BY DESIGN FOR LEGACY COMMERCIALIZED ENZYME REPLACEMENT THERAPIES

Anup Agarwal, Shire Pharmaceuticals
anagarwal@shire.com
Eric Hayduk, Shire Pharmaceuticals

Key Words: QbD, enzyme replacement

Quality by Design (QbD) has been widely adopted by the pharmaceutical industry as a tool for transforming development, manufacture, and commercialization of drug products. QbD ensures that quality is built into a manufacturing process to consistently produce desired product. As per a FDA guidance¹, QbD should be employed at the product development stage to ensure manufacture of a product with predefined quality. Here we present a retrospective QbD approach employed at Shire to define an improved control strategy for a commercial process using risk-based process understanding and characterization. Key challenges and considerations of implementing a QbD strategy on a commercial process are presented with examples of critical quality attribute review, parameter impact assessment, parameter classification review and updated control strategy.

¹US Food and Drug Administration. Guidance for industry: Q10 quality systems approach to pharmaceutical cGMP regulations (FDA, Rockville, MD, September 2006).